Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Significant breakthrough in understanding the cause of bile duct cancer

A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.

15 May 2012

Researchers identify new biomarker and therapeutic target for pancreatic cancer

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.

15 May 2012

$Onconova advances rigosertib into new Phase II study for refractory MDS$

Onconova advances rigosertib into new Phase II study for refractory MDS

Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib, an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.

11 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

Pancreatic cancer could be better managed at specialized surgical centres

Pancreatic cancer is one of Australia's most lethal cancers and according to a surgeon it could be better treated by conducting complex surgical procedures in specialised centres. Pancreatic cancer is the fourth biggest cancer killer in Australia.

8 May 2012

Researchers identify new functions of cohesin SA1 that are relevant for cancer and CdLS

Cohesin is a ring-shaped protein complex involved in the spatial organization of the genome and in mitotic chromosome structure. Vertebrate somatic cells have two versions of cohesin that contain either SA1 or SA2, but their functional specificity has been largely ignored. Researchers of the Spanish National Cancer Research Centre (CNIO) under the direction of Ana Losada have identified new functions of cohesin SA1 that are relevant for two human diseases, cancer and Cornelia de Lange Syndrome.

4 May 2012

Comorbidities common among patients with COPD

Comorbidities are common among patients with chronic obstructive pulmonary disease (COPD), and a number of these comorbidities are independently associated with an increased mortality risk, according to a new study.

4 May 2012

Trovagene completes PCR assay development for detection of K-RAS mutations

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.

30 Apr 2012

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

Kras gene triggers metabolic changes that fuel cancer cells

Researchers at Dana-Farber Cancer Institute have shown that advanced pancreatic cancers in mice can't survive without continued expression of a mutant oncogene that "rewires" key metabolic pathways to fuel the cancer cells.

27 Apr 2012

Combination of Velcade and Fasudil could treat NSCLC

A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.

27 Apr 2012

A melanoma cloaking protein

Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

Melanomas express B7-H1 protein to hide from T-cells

26 Apr 2012

Study confirms overuse of blood transfusions during surgery

Citing the lack of clear guidelines for ordering blood transfusions during surgery, Johns Hopkins researchers say a new study confirms there is still wide variation in the use of transfusions and frequent use of transfused blood in patients who don't need it.

25 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

TJUH medical oncologist to receive ASCO Humanitarian Award

Edith Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center (KCC) and Clinical Professor of Medicine and Medical Oncology in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, has been named the 2012 recipient of the American Society of Clinical Oncology (ASCO) Humanitarian Award for her personification of the society's mission and values, and for going above and beyond the call of duty in providing outstanding patient care.

6 Apr 2012

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Research from The Cancer Institute of New Jersey (CINJ) shows that a series of vaccine injections given directly into a pancreatic cancer tumor is shown to be associated with stable disease in patients who are not candidates for surgery.

5 Apr 2012

More than 4 in 10 people at high risk for hereditary pancreatic cancer have small lesions

A team of scientists led by Johns Hopkins researchers have found that more than four in 10 people considered at high risk for hereditary pancreatic cancer have small pancreatic lesions long before they have any symptoms of the deadly disease.

5 Apr 2012

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.

4 Apr 2012